Ignite Creation Date:
2024-05-06 @ 12:47 AM
Last Modification Date:
2024-10-26 @ 10:54 AM
Study NCT ID:
NCT01657682
Status:
COMPLETED
Last Update Posted:
2023-11-30
First Post:
2012-07-31
Brief Title:
A Phase II Study of Crenolanib in RelapsedRefractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations
Sponsor:
Arog Pharmaceuticals Inc
Organization:
Arog Pharmaceuticals Inc
Key Dates - Follows AllAPIJSON File Order
Start Date:
2012-10
Start Date Type:
None
Primary Completion Date:
2019-04
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-04
Completion Date Type:
ACTUAL
First Submit Date:
2012-07-31
First Submit QC Date:
August 1 2012
Study First Post Date:
2012-08-06
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2023-11-30
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-11-07
Last Update Post Date:
2023-11-30
Last Update Post Date Type:
ACTUAL